Precision medicine is a model of personalized therapy driven by modern technology. At present, a large number of cancer research results have been applied to precision medicine. The study of precision medicine for cancer has become a bridge between theoretical research and clinical applications. The plasticity and spatial and temporal heterogeneity of cancer glucose metabolism lead to huge differences in the response of different patients to cancer treatment drugs, and even the same patient shows huge differences in the response to the same drug at different stages of disease progression. Therefore, cancer glucose metabolism is of great significance for the development of precision medicine for cancer. CD BioGlyco can process patient-derived tumor samples provided by customers and provide personalized model building and precision treatment strategy screening services based on the MOPCGM platform.
Fig. 1 Overview of precision oncology (Dupont CA, et al., 2021)
As the cornerstone of precision medicine, biomarkers are of great significance in various research in the field of cancer treatment. At present, clinicians can formulate personalized therapy plans for patients based on cancer biomarkers determined by DNA, RNA, protein expression, etc. However, there is still a big difference between the conclusions based on these biomarker analyses and the results of clinical therapy. The study of metabolite biomarkers can provide more information for the diagnosis and classification of cancer, and for clinicians to formulate personalized treatment plans, which is helpful for the clinical application of scientific research results.
CD BioGlyco can help customers screen and identify personalized biomarkers of glucose metabolism, providing solutions for researchers' case reporter projects.
In cancer therapy, a patient's response to a therapeutic drug is often variable, and a patient's response to a drug is influenced by a variety of factors, among which the patient's individual metabolic level or the ability to utilize the drug has a significant impact. Cancer glucose metabolomics analysis, as an important part of pharmacogenomics analysis, will greatly promote the development of precision therapy.
CD BioGlyco is able to build cell models, organoid models, and animal models based on the samples provided by customers, and quickly and efficiently provide predictions of personalized intervention strategies with therapeutic effects on samples through the MOPCGM platform.
CD BioGlyco provides rapid and effective solutions to help customers promote the research of cancer glucose metabolism and precision medicine. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.